drugset / Trial / NCT00803101

An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure

NCT00803101 ↗

Phase 3 Completed 176 enrolled CSL Behring
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by vitamin K antagonists in subjects who require immediate correction of international normalized ratio (INR) because of emergency surgery.

Timeline

Start
2009-02
Primary completion
2012-11
Completion
2013-02

Outcome

Met primary endpoint

paper Effective haemostasis was achieved in 78 (90%) patients in the 4F-PCC group compared with 61 (75%) patients in the plasma group PMID 25728933 ↗

paper demonstrating both non-inferiority and superiority of 4F-PCC over plasma (difference 14·3%, 95% CI 2·8-25·8). PMID 25728933 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Beriplex Unknown — Intravenous
Comparator Fresh Frozen Plasma Protein / enzyme biologic — Intravenous

Indications

No indication recorded.